CELEST
Live / Allowed — Notice of allowance issued (as of 21 Oct 2025)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 11 Oct 2023 filing date already counts against anyone who files later.
Record
- Serial number
- 98219801
- Mark type
- Stylized text
- Filed
- 11 Oct 2023
- Published for opposition
- 26 Aug 2025
- Attorney of record
- Jonathan M. Gelchinsky
Goods and services
- Class 001 — Chemicals: Chemical and biological agents for scientific and research use, namely, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acids and modified nucleic acids, namey, short RNAs and messenger RNAs; nucleic acid sequences for scientific purposes, research purposes, and laboratory purposes other than medical and veterinary purposes
- Class 005 — Pharmaceuticals: Drug delivery agents in the form of lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds directed to lipid nanoparticles for the purpose of delivering pharmaceutical preparations to specific target tissue sites; drug delivery agents in the form of lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds and agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations; drug delivery agents consisting of pharmaceutical preparations and therapeutic agents that facilitate the release and delivery of a wide variety of pharmaceutical preparations for RNA, gene therapy and mRNA regulation; drug delivery agents consisting of pharmaceutical and biological preparations for medical use that facilitate the release and delivery of a wide variety of pharmaceutical preparations for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; drug delivery agents consisting of pharmaceutical preparations that facilitate the release and delivery of a wide variety of pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation; pharmaceutical preparations, namely, vaccines
- Class 042 — Scientific and technological services: Research and development in the field of technology and engineering, lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, drug delivery agents and RNAs for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of lipids, lipid nanoparticles, lipid nanoparticle conjugates, lipid formulations, RNAs, namely, developing molecular and cellular biology reagents, techniques, drug delivery agents and assays for use in pharmaceutical and biomedical industry
Owner
- ReNAgade Therapeutics Management, Inc., Watertown, MA, US
- ReNAgade Therapeutics Management, Inc., Watertown, MA, US
Prosecution history
- 21 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Aug 2025 — PUBLISHED FOR OPPOSITION
- 20 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 30 Oct 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Oct 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 30 Oct 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 04 Oct 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 04 Oct 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 04 Oct 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 04 Oct 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 04 Oct 2024 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 15 Jul 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 15 Jul 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED